Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
NEW YORK, March 04, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of GW Pharmaceuticals plc securities (NASDAQ:GWPH) from December 4, 2014 through January 8, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for GW Pharmaceuticals investors under the federal securities laws.
To join the GW Pharmaceuticals class action, go to the firm’s website at http://rosenlegal.com/cases-821.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period, Defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) GW Pharmaceuticals lacked effective internal financial controls; (2) GW Pharmaceuticals lacked effective controls over completeness and valuation of clinical trial accruals; and (3) as a result, Defendants’ statements about GW Pharmaceuticals’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 21, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-821.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
